Related Experiment Video
Updated: Sep 10, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing
Yuya Kawamoto1, Masahiro Suzuki2, Mitsunaga Iwata3
1Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan guchonvskite@yahoo.co.jp.
Abstract:
A man in his 70s was admitted to an intensive care unit with severe COVID-19 and treated with dexamethasone and tocilizumab. After recovery from COVID-19, he developed Clostridium butyricum bacteraemia and non-occlusive mesenteric ischaemia, with fatal outcome. He had been prescribed C. butyricum MIYAIRI 588 fine granules as probiotics for a month. The genome sequences of the C. butyricum isolate from the blood culture and C. butyricum MIYAIRI 588 fine granules were identical by single nucleotide polymorphism analysis. This is the first case of definitive probiotics-related C. butyricum bacteraemia after treatment of severe COVID-19.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Related Concept Videos
Probiotics
Introduction to the Human Microbiota
Dysbiosis of the Gut Microbiota
Bacterial Gastroenteritis
Clinical Significance of Antibiotic Resistance